Quest Diagnostics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Quest Diagnostics (DGX).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

7Buy

8Hold

Consensus RatingNeutral# Analysts15Avg. Consensus PT$213Upside to Avg. PT-7.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$250→$260
Sep 21, 2026	Truist Securities	David Macdonald	PT Raise	Hold	$250→$260
Sep 8, 2026	UBS	Kevin Caliendo	PT Raise	Neutral	$232→$245
Jul 28, 2026	JP Morgan	Lisa Gill	PT Raise	Neutral	$220→$250
Jul 24, 2026	UBS	Kevin Caliendo	PT Raise	Neutral	$220→$232
Jul 24, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$235→$260
Jul 24, 2026	Truist Securities	David Macdonald	PT Raise	Hold	$225→$250
Jul 24, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$230→$250
Jul 24, 2026	Baird	Eric Coldwell	PT Raise	Neutral	$236→$255
Jul 13, 2026	Baird	Eric Coldwell	PT Raise	Neutral	$232→$236
Apr 22, 2026	UBS	Kevin Caliendo	PT Raise	Neutral	$210→$220
Apr 22, 2026	Baird	Eric Coldwell	PT Raise	Neutral	$224→$229
Apr 22, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$225→$230
Apr 22, 2026	Truist Securities	David Macdonald	PT Raise	Hold	$220→$225
Apr 8, 2026	Evercore ISI Group	Elizabeth Anderson	PT Cut	In-Line	$220→$210
Feb 12, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$210→$235
Feb 11, 2026	Truist Securities	David Macdonald	PT Raise	Hold	$205→$220
Feb 11, 2026	UBS	Kevin Caliendo	PT Raise	Neutral	$190→$210
Feb 11, 2026	Evercore ISI Group	Elizabeth Anderson	PT Raise	In-Line	$190→$220
Feb 11, 2026	Barclays	Stephanie Davis	PT Raise	Overweight	$210→$225

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260

Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $250 to $260.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $250 to $260.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245

UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $245.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250

JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $220 to $250.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260

Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $235 to $260.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $225 to $250.

Benzinga Newsdesk

Quest Diagnostics Inc

Quest Diagnostics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260

PRO
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260

PRO
UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245

PRO
JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250

PRO
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260

PRO
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250

People Also Watch

People Also Watch

Quest Diagnostics Inc

Quest Diagnostics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260

PROTruist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260

PROUBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245

PROJP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250

PROMizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260

PROTruist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250

People Also Watch

People Also Watch

PRO
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260

PRO
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260

PRO
UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245

PRO
JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250

PRO
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260

PRO
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250